Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
The Breakwater study hits on overall survival with "unprecedented" data.
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
Crunch time approaches for UroGen.
